Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study.
[inclusion body myositis]
In
sIBM
,
an
inflammatory
process
mediated
by
cytotoxic
T
cells
and
cytokines
in
conjunction
with
a
degenerative
process
,
deposits
of
beta
amyloid
and
misfolded
proteins
appear
to
be
the
main
culprits
in
disease
pathogenesis
.
IL
-
1
β
may
play
a
key
role
because
it
is
upregulated
in
sIBM
myofibers
,
co
-localizes
with
Amyloid
Precursor
Protein
(
APP
)
and
promotes
the
production
of
APP
and
amyloid
deposits
.
We
performed
a
small
,
pilot
study
to
examine
whether
anakinra
,
an
IL
1
receptor
antagonist
could
benefit
sIBM
patients
.
Four
patients
with
biopsy-proven
sIBM
received
anakinra
for
a
mean
period
of
7
.
7
months
.
No
improvement
in
muscle
strength
or
stabilization
was
noted
in
any
of
the
patients
based
on
grip
strength
and
MRC
measurements
.
The
treatment
failure
may
be
due
to
insufficiency
of
anakinra
to
suppress
the
intramuscular
IL
1
,
the
short
study
period
,
or
the
irrelevance
of
IL
1
in
the
disease
process
.
Diseases
Validation
Diseases presenting
"stabilization was noted in any of the patients based on grip strength and mrc measurements"
symptom
inclusion body myositis
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom